Interaction between triglyceride-glucose index and body mass index on pregnancy loss in Chinese women with polycystic ovary syndrome: a secondary analysis of a randomized clinical trial
Abstract
OBJECTIVE: This study aims whether triglyceride-glucose Index (TyG) / body mass index (BMI) mediates associations of BMI/TyG with insulin resistance (IR), metabolic syndrome (MetS), and pregnancy outcomes and the extent of interaction or joint relations of TyG and BMI with IR, MetS, and pregnancy outcomes. METHOD: This study is a secondary analysis of the Polycystic Ovary Syndrome Acupuncture and Clomiphene Trial. Eight hundred fifty-five women with PCOS were recruited from 27 hospitals in mainland China between 2012 and 2015. Mediation, interaction and joint analysed of BMI and TyG on IR, MetS and pregnancy outcomes, using generalized linear model, stepwise regression, multinomial logistic regression, and restricted cubic spline. The predictive performance of TyG + BMI for Pregnancy Loss was determined using receiver operating characteristic curve analysis. RESULTS: A significant interaction between BMI and TyG was observed for pregnancy loss (P < 0.05). Simple effects analysis further revealed distinct patterns across TyG strata: Within the TyG T2 tertile, pregnancy loss differed significantly between BMI < 24.0 kg/m², BMI 24.0–27.9 kg/m², and BMI ≥ 28.0 kg/m². Within the TyG T3 tertile, both BMI 24.0–27.9 kg/m² and BMI ≥ 28.0 kg/m² showed significant differences compared to BMI < 24.0 kg/m². Conversely, under BMI stratification: in the BMI ≥ 28.0 kg/m² subgroup, TyG T2 and T3 exhibited significant differences relative to TyG T1. The joint association analysis demonstrated…
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.